Just found this –
http://www.prnewswire.com/news-releases/biotheranostics-announces-commercial-availability-of-expanded-tumor-type-database-for-cancertype-idr-and-the-launch-of-kras-testing-86332772.html
“This new database enhances the ability of the CancerTYPE ID assay to discriminate between clinically relevant metastatic tumors occurring within the GI tract, head and neck, lung (squamous, non-squamos adenocarcinoma, and mesothelioma), and intestine, while incorporating coverage of certain tumor types that frequently present diagnostic challenges such as cholangiocarcinoma, ovarian-mucinous adenocarcinoma, and small intestinal carcinoma. “
Gavin